Comments
Loading...

Janux Therapeutics Analyst Ratings

JANXNASDAQ
Logo brought to you by Benzinga Data
$24.77
At close: May 21 EDT
$24.77
0.000.00%
Pre-Market: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$200.00
Lowest Price Target1
$41.00
Consensus Price Target1
$81.18

Janux Therapeutics Analyst Ratings and Price Targets | NASDAQ:JANX | Benzinga

Janux Therapeutics Inc has a consensus price target of $81.18 based on the ratings of 12 analysts. The high is $200 issued by Cantor Fitzgerald on December 11, 2024. The low is $41 issued by Scotiabank on February 28, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Scotiabank, and Cantor Fitzgerald on March 3, 2025, February 28, 2025, and December 11, 2024, respectively. With an average price target of $103.67 between HC Wainwright & Co., Scotiabank, and Cantor Fitzgerald, there's an implied 318.52% upside for Janux Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Dec 24
0
0
0
0
Feb
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Scotiabank
Cantor Fitzgerald
Stifel
Leerink Partners

1calculated from analyst ratings

Analyst Ratings for Janux Therapeutics

Buy NowGet Alert
03/03/2025Buy Now182.6%HC Wainwright & Co.
Swayampakula Ramakanth50%
$70 → $70ReiteratesBuy → BuyGet Alert
02/28/2025Buy Now65.52%Scotiabank
George Farmer38%
$62 → $41MaintainsSector PerformGet Alert
12/11/2024Buy Now707.43%Cantor Fitzgerald
Josh Schimmer51%
$200 → $200ReiteratesOverweight → OverweightGet Alert
12/04/2024Buy Now150.3%Scotiabank
George Farmer38%
$42 → $62MaintainsSector PerformGet Alert
12/03/2024Buy Now364.27%Stifel
Bradley Canino40%
$70 → $115MaintainsBuyGet Alert
12/03/2024Buy Now267.38%Leerink Partners
Jeffrey La Rosa19%
$79 → $91MaintainsOutperformGet Alert
12/03/2024Buy Now182.6%HC Wainwright & Co.
Swayampakula Ramakanth50%
$63 → $70MaintainsBuyGet Alert
11/22/2024Buy Now218.93%Leerink Partners
Jeffrey La Rosa19%
→ $79Initiates → OutperformGet Alert
11/07/2024Buy Now154.34%HC Wainwright & Co.
Swayampakula Ramakanth50%
$63 → $63ReiteratesBuy → BuyGet Alert
11/07/2024Buy Now303.71%Cantor Fitzgerald
Josh Schimmer51%
$100 → $100ReiteratesOverweight → OverweightGet Alert
10/24/2024Buy Now178.56%UBS
David Dai25%
→ $69Initiates → BuyGet Alert
09/16/2024Buy Now303.71%Cantor Fitzgerald
Josh Schimmer51%
$100 → $100ReiteratesOverweight → OverweightGet Alert
09/06/2024Buy Now182.6%Stifel
Bradley Canino40%
→ $70Initiates → BuyGet Alert
08/19/2024Buy Now154.34%HC Wainwright & Co.
Swayampakula Ramakanth50%
$63 → $63ReiteratesBuy → BuyGet Alert
08/09/2024Buy Now69.56%Scotiabank
George Farmer38%
$47 → $42MaintainsSector PerformGet Alert
08/08/2024Buy Now303.71%Cantor Fitzgerald
Josh Schimmer51%
$100 → $100ReiteratesOverweight → OverweightGet Alert
08/08/2024Buy Now198.75%Wedbush
Robert Driscoll44%
$74 → $74ReiteratesOutperform → OutperformGet Alert
05/30/2024Buy Now89.75%Scotiabank
George Farmer38%
→ $47Initiates → Sector PerformGet Alert
05/13/2024Buy Now154.34%HC Wainwright & Co.
Swayampakula Ramakanth50%
$50 → $63MaintainsBuyGet Alert
05/09/2024Buy Now303.71%Cantor Fitzgerald
Josh Schimmer51%
$100 → $100ReiteratesOverweight → OverweightGet Alert
05/08/2024Buy Now198.75%Wedbush
Robert Driscoll44%
$53 → $74MaintainsOutperformGet Alert
04/16/2024Buy Now182.6%JonesTrading
Soumit Roy33%
→ $70Initiates → BuyGet Alert
03/21/2024Buy Now150.3%BTIG
Kaveri Pohlman25%
→ $62Initiates → BuyGet Alert
03/20/2024Buy Now303.71%Cantor Fitzgerald
Josh Schimmer51%
→ $100Initiates → OverweightGet Alert
03/13/2024Buy Now93.78%B of A Securities
Geoff Meacham60%
$24 → $48MaintainsBuyGet Alert
03/11/2024Buy Now101.86%HC Wainwright & Co.
Swayampakula Ramakanth50%
$35 → $50MaintainsBuyGet Alert
02/27/2024Buy Now113.97%Wedbush
David Driscoll52%
$24 → $53MaintainsOutperformGet Alert
11/13/2023Buy Now41.3%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $35ReiteratesBuy → BuyGet Alert
11/08/2023Buy Now-3.11%Wedbush
Robert Driscoll44%
→ $24ReiteratesOutperform → OutperformGet Alert
08/10/2023Buy Now-3.11%Wedbush
Robert Driscoll44%
→ $24ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now41.3%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $35ReiteratesBuy → BuyGet Alert
07/18/2023Buy Now-3.11%Wedbush
Robert Driscoll44%
→ $24ReiteratesOutperform → OutperformGet Alert
07/18/2023Buy Now41.3%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $35ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now-3.11%Wedbush
Robert Driscoll44%
→ $24Reiterates → OutperformGet Alert
05/10/2023Buy Now41.3%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $35Reiterates → BuyGet Alert
04/06/2023Buy Now-3.11%Wedbush
Robert Driscoll44%
→ $24Initiates → OutperformGet Alert
03/13/2023Buy Now41.3%HC Wainwright & Co.
Swayampakula Ramakanth50%
→ $35Reiterates → BuyGet Alert
11/14/2022Buy Now—William Blair
Matt Phipps23%
—Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Janux Therapeutics (JANX) stock?

A

The latest price target for Janux Therapeutics (NASDAQ:JANX) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $70.00 expecting JANX to rise to within 12 months (a possible 182.60% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Janux Therapeutics (JANX)?

A

The latest analyst rating for Janux Therapeutics (NASDAQ:JANX) was provided by HC Wainwright & Co., and Janux Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Janux Therapeutics (JANX)?

A

There is no last upgrade for Janux Therapeutics

Q

When was the last downgrade for Janux Therapeutics (JANX)?

A

There is no last downgrade for Janux Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Janux Therapeutics (JANX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.

Q

Is the Analyst Rating Janux Therapeutics (JANX) correct?

A

While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a reiterated with a price target of $70.00 to $70.00. The current price Janux Therapeutics (JANX) is trading at is $24.77, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch